PPAR-γ receptor ligands: novel therapy for pituitary adenomas
J. Clin. Invest. Anthony P. Heaney, et al. 111:1381 doi:10.1172/JCI16575 [Go to this article.]

Figure 7
Rosiglitazone treatment retards growth of established pituitary gonadotroph tumors in vivo (n = 5). Mice were inoculated subcutaneously with αT3 gonadotroph pituitary tumor cells (∼200,000) and tumors were allowed to develop. By 3 weeks after inoculation, all animals had developed large visible tumors and were then randomized to receive either oral rosiglitazone (150 mg/kg/d) (n = 5) or vehicle (n = 5). Initial tumor volumes were comparable in the vehicle- and rosiglitazone-treated groups. After 4 more weeks, vehicle-treated control animals had become debilitated, necessitating euthanization. Tumor weights were abrogated in the rosiglitazone-treated animals. *P = 0.005.